ZDHHC7 Antibody

What is ZDHHC7 and why is it important in cellular research?

ZDHHC7 (zinc finger DHHC-type containing 7) functions as a palmitoyltransferase with broad substrate specificity. It catalyzes the addition of palmitate to various proteins including JAM3, SNAP25, DLG4/PSD95, and sex steroid hormone receptors (ESR1, PGR, and AR) . This post-translational modification regulates protein targeting to the plasma membrane and influences rapid intracellular signaling pathways . ZDHHC7's role in palmitoylating proteins like Scribble (SCRIB) is particularly significant as it directly impacts cell polarity, membrane targeting, and tumor suppression mechanisms, making it a valuable target for cancer research .

What are the optimal applications and dilutions for ZDHHC7 antibodies?

Based on validation data from multiple commercial antibodies, ZDHHC7 antibodies are primarily optimized for:

Additional considerations:

• Antibody performance is sample-dependent; titration is recommended in each testing system

• Western blot applications typically detect ZDHHC7 at 45-49 kDa, though the calculated molecular weight is 39 kDa

• Most commercial antibodies show reactivity with human samples, with some cross-reactivity to mouse and rat

What storage conditions maximize ZDHHC7 antibody stability and performance?

ZDHHC7 antibodies should be stored at -20°C for optimal stability. Most preparations remain stable for one year after shipment when stored properly . The typical storage buffer consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For antibodies supplied in smaller volumes (20μl), preparations may contain 0.1% BSA as a stabilizer . Aliquoting is generally unnecessary for -20°C storage, which simplifies laboratory handling procedures .

How can researchers experimentally detect and quantify ZDHHC7-mediated protein palmitoylation?

Multiple complementary approaches can be employed to investigate ZDHHC7-mediated palmitoylation:

• Chemical reporter method: Metabolic labeling with alkyne-containing palmitate analogs (e.g., Alk14) followed by click chemistry with biotin-azide allows for palmitoylated protein detection . This approach was successfully employed to demonstrate ZDHHC7-mediated palmitoylation of SCRIB and NLRP3 .

• Co-transfection studies: Transfecting ZDHHC7 constructs (wild-type or enzymatically inactive mutants) alongside target proteins provides evidence of enzyme-substrate relationships. For example, expression of ZDHHC7 significantly enhanced SCRIB palmitoylation levels in HEK293A cells compared to other ZDHHC enzymes .

• Palmitate-analog inhibition: Treatment with 2-bromopalmitate (2-BP) can inhibit palmitoylation, providing a pharmacological approach to investigate functional consequences. Researchers demonstrated that 2-BP treatment inhibited GSDMD cleavage and IL-1β secretion in THP-1 cells and human primary macrophages, confirming the functional importance of ZDHHC7-mediated palmitoylation .

• Site-directed mutagenesis: Mutation of specific cysteine residues in substrate proteins can identify palmitoylation sites. This approach revealed that SCRIB is palmitoylated at two conserved membrane-proximal cysteine residues, and palmitoylation-deficient mutants displayed mislocalization and loss of tumor suppressive function .

What are the challenges in generating and validating ZDHHC7 knockout models?

Researchers face several technical challenges when developing ZDHHC7 knockout models:

• Antibody specificity issues: Commercial antibodies for ZDHHC7 detection may produce nonspecific bands, complicating validation of knockout efficiency . As noted in one study: "The results are not completely consistent as the commercial antibody gives many nonspecific bands, and complicated with the detection" .

• Alternative validation approaches: When antibody detection is problematic, researchers should employ alternative methods:

  • qRT-PCR to confirm reduced transcript levels

  • Use of multiple guide RNAs for CRISPR/Cas9-mediated knockout

  • Functional assessment of known ZDHHC7 substrates to confirm loss of enzymatic activity

• CRISPR/Cas9 design considerations: Guide RNA selection is critical for efficient knockout. In one study, guide-RNA1 showed good knockout efficiency in PrEC cells, while other constructs had variable efficacy . Multiple guide RNAs should be tested to identify the most effective constructs.

• Phenotypic confirmation: Beyond molecular validation, ZDHHC7 knockout should be confirmed by examining known cellular phenotypes, such as SCRIB mislocalization or reduced NLRP3 inflammasome activation .

How does ZDHHC7-mediated palmitoylation of Scribble regulate cell polarity and tumor suppression?

ZDHHC7 plays a crucial role in tumor suppression through its palmitoylation of Scribble (SCRIB):

• Membrane localization mechanism: ZDHHC7-mediated palmitoylation occurs at two conserved cysteine residues in SCRIB, which is critical for proper membrane targeting . Palmitoylation-deficient mutants of SCRIB fail to localize to cell-cell junctions, leading to disruption of cell polarity .

• Downstream pathway regulation: Properly localized SCRIB suppresses multiple oncogenic pathways:

  • YAP pathway inhibition

  • MAPK pathway suppression

  • PI3K/Akt pathway regulation

• Functional consequences: ZDHHC7 knockout or expression of palmitoylation-deficient SCRIB mutants results in:

  • Disruption of epithelial cell polarity

  • Loss of SCRIB's tumor suppressive activities

  • Enhanced HRasV12-induced cell invasion

• Experimental evidence: Immunofluorescence and confocal microscopy studies demonstrated that palmitoylation of SCRIB is essential for plasma membrane targeting and establishment of epithelial cell polarity . Loss of ZDHHC7-mediated palmitoylation disrupts this process, suggesting a mechanism for how SCRIB mislocalization contributes to tumorigenesis .

What are the methodological approaches for studying ZDHHC7's role in inflammasome activation?

Recent research has revealed ZDHHC7's critical function in inflammasome regulation through palmitoylation of NLRP3:

• Gene expression profiling: Analysis of Zdhhc gene expression in bone marrow-derived macrophages (BMDMs) and human classical monocytes identified Zdhhc7 as having predominant expression compared to other family members, suggesting its important role in inflammasome regulation .

• Palmitoylation detection: NLRP3 palmitoylation can be detected using the Alk14 labeling method, which demonstrated that ZDHHC7 enzymatic activity is essential for this modification .

• Functional validation approaches:

  • ZDHHC7 knockout in macrophages inhibits caspase-1 and GSDMD cleavage and IL-1β secretion after inflammasome activation

  • Pharmacological inhibition with ZDHHC inhibitors (2-BP, MY-D4) suppresses GSDMD cleavage and IL-1β secretion

  • 2-BP-Alk probe labeling confirmed that 2-BP covalently binds to ZDHHC7 in inflammasome-activated BMDMs

• Mechanistic dissection: Experiments demonstrated that ZDHHC7 affects the activation step of the NLRP3 inflammasome rather than the priming step, as Zdhhc7 knockout did not affect mRNA or protein levels of NLRP3, pro-caspase-1, or full-length GSDMD .

How can researchers optimize antibody specificity for ZDHHC7 detection?

Given the challenges with antibody specificity reported in the literature , several approaches can enhance detection specificity:

• Validation with positive controls: Use established positive control samples such as PC-3 cells, MCF-7 cells, A-431 cells, or mouse lung tissue, which have been confirmed to express ZDHHC7 .

• Recombinant protein controls: Employ recombinant ZDHHC7 protein fragments as controls. For example, Human ZDHHC7 (aa 1-29) Control Fragment can be used for blocking experiments with the corresponding antibody at a 100x molar excess based on concentration and molecular weight .

• Multiple antibody validation: Test multiple antibodies targeting different epitopes of ZDHHC7. Available antibodies target various regions including the C-terminus and internal domains .

• Knockout validation: Generate ZDHHC7 knockout cells as negative controls using CRISPR/Cas9 technology. While this approach presents its own challenges, it provides the gold standard for antibody validation .

• Pre-adsorption testing: Pre-incubate the antibody with its immunizing peptide (when available) for 30 minutes at room temperature before application to verify binding specificity .

What strategies address inconsistent detection of ZDHHC7 in Western blot experiments?

When encountering variable results in ZDHHC7 detection:

• Optimize protein extraction: ZDHHC7 is a membrane-associated protein, requiring efficient membrane protein extraction methods. Use detergent-based lysis buffers optimized for membrane proteins.

• Consider sample preparation: ZDHHC7 has reported differences between calculated (39 kDa) and observed molecular weights (45-49 kDa) , suggesting post-translational modifications that may affect detection.

• Alternative detection methods: When Western blot results are inconsistent, consider complementary approaches:

  • qRT-PCR for transcript-level analysis

  • Immunofluorescence for localization studies (primarily Golgi localization)

  • Functional assays examining palmitoylation of known substrates

• Dilution optimization: The recommended dilution range for Western blot applications is broad (1:500-1:2000) . Systematic titration should be performed to determine optimal concentration for each experimental system.

What experimental design considerations are essential when investigating ZDHHC7-substrate relationships?

When examining potential ZDHHC7 substrates:

• Substrate screening approach: Co-transfection of ZDHHC7 with potential substrate proteins and metabolic labeling with palmitate analogs provides initial evidence of enzyme-substrate relationships . This approach successfully identified SCRIB as a ZDHHC7 substrate.

• Controls for specificity: Compare ZDHHC7 with other DHHC family members to establish substrate preferences. For example, expression of ZDHHC3 or ZDHHC7 enhanced SCRIB palmitoylation, with ZDHHC7 showing greater potency .

• Functional validation: Demonstrate that ZDHHC7-mediated palmitoylation affects substrate function through:

  • Localization studies (palmitoylation often affects membrane targeting)

  • Downstream signaling analysis

  • Phenotypic assays relevant to the substrate's known function

• Site identification: Use site-directed mutagenesis to identify specific cysteine residues modified by ZDHHC7. For SCRIB, palmitoylation occurs at two conserved membrane-proximal cysteine residues .

• Catalytic mutant controls: The enzymatically inactive mutant of ZDHHC7 (ZDHHS7) serves as an excellent negative control, as it fails to restore substrate palmitoylation in knockout cells .

How might ZDHHC7-targeted therapeutic approaches evolve based on current research?

Current research suggests several promising therapeutic directions:

• Inflammasome modulation: ZDHHC7 inhibition suppresses NLRP3 inflammasome activation, suggesting potential applications in inflammatory diseases. ZDHHC inhibitors such as 2-BP and MY-D4 have demonstrated efficacy in inhibiting GSDMD cleavage and IL-1β secretion in both mouse and human macrophages .

• Cancer intervention strategies: ZDHHC7's role in maintaining SCRIB localization and tumor suppressive functions indicates potential cancer therapeutic applications. Restoring ZDHHC7 expression or function in cancers might help reestablish cell polarity and suppress oncogenic pathways .

• Targeted drug delivery: Understanding ZDHHC7's role in protein membrane targeting could inform strategies for enhancing drug delivery to specific cellular compartments by exploiting palmitoylation mechanisms.

• Biomarker development: ZDHHC7 expression levels or activity could potentially serve as biomarkers for cancer progression or inflammatory conditions, based on its altered expression or function in disease states .

What emerging technologies might enhance detection and functional analysis of ZDHHC7-mediated palmitoylation?

Several technological advances show promise:

• Proximity labeling approaches: BioID or APEX2-based proximity labeling could identify novel ZDHHC7 substrates and interacting proteins in their native cellular environment.

• Palmitoylation-specific proteomics: Advanced mass spectrometry techniques combined with clickable palmitate analogs enable system-wide identification of palmitoylated proteins, allowing comprehensive mapping of the ZDHHC7 substrate landscape.

• Super-resolution microscopy: Techniques such as STORM or PALM could provide unprecedented spatial resolution of ZDHHC7 localization and its dynamic interactions with substrates at the Golgi apparatus and other cellular membranes.

• CRISPR screens: Genome-wide CRISPR screens in the context of ZDHHC7 deficiency could identify synthetic lethal interactions and novel functional relationships, potentially revealing unexpected roles beyond known substrates.

• Organoid models: Patient-derived organoids offer more physiologically relevant systems for studying ZDHHC7 function in tissue-specific contexts, particularly in cancer and inflammatory conditions.